2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 309

Periarticular Tibial Knee Bone Mineral Density Is Associated with Knee Symptoms

Osteoarthritis – Clinical Aspects - Poster I

9:00AM-11:00AM: Abstract Number: 875

Pericardial Involvement in Biopsy-Proven Giant-Cell Arteritis (GCA) Patients Detected By CT Angiography (CTA): Prevalence at Diagnosis and Outcome with Glucocorticoid (GC) Treatment

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 851

Perioral Autologous FAT Transplantation Is More Effective THAN Hyaluronic Acid Filler on Scleroderma Skin Fibrosis: Results from a LONG TERM Controlled Study

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I

9:00AM-11:00AM: Abstract Number: 366

Peripheral Osteoclastogensis Is Coming Back Along with Inflammation Twelve Months after Rituximab Therapy

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 866

Perivascular Inflammation in Temporal Artery Biopsies That Are Negative for Arteritis: Incidental or Harbinger?

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 251

Persistent Pruritic Skin Lesions with Dyskeratotic Cells in Upper Layer of Epidermis Are Specific and Associated with High Levels of Serum IL-18 in Adult-Onset Still’s Disease

Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

9:00AM-11:00AM: Abstract Number: 375

Persistent Tactile Allodynia in Male Arthritic Mice Is Accompanied By Sprouting of Sensory and Sympathetic Nerve Fibers

Pain – Basic and Clinical Aspects - Poster

9:00AM-11:00AM: Abstract Number: 192

Pharmacodynamic and Pharmacokinetic Study of Verinurad in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment: A Phase 1, Open-Label Study

Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

9:00AM-11:00AM: Abstract Number: 196

Pharmacodynamic Effects and Safety of Verinurad in Combination with Allopurinol Versus Allopurinol Alone in Adults with Gout: A Phase 2a, Open-Label Study

Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

9:00AM-11:00AM: Abstract Number: 197

Pharmacodynamic Effects and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone in Adults with Gout: A Phase 2a, Open-Label Study

Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

9:00AM-11:00AM: Abstract Number: 195

Pharmacodynamics, Pharmacokinetics, and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone and Verinurad Alone in Japanese Adults with Gout or Asymptomatic Hyperuricemia: A Phase 2a, Open-Label Study

Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

9:00AM-11:00AM: Abstract Number: 615

Pharmacokinetic Similarity of ABP 710 Relative to Infliximab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 756

Pharmacokinetics and Exposure-Response Relationship of Belimumab Administered Subcutaneously to SLE Patients

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 194

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects with Gout

Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

9:00AM-11:00AM: Abstract Number: 191

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Febuxostat in Healthy Adult Male Subjects

Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].